US2017319617A1PendingUtilityA1

Composition for the treatment of disease

56
Assignee: FERRING BVPriority: Mar 25, 2013Filed: May 18, 2017Published: Nov 9, 2017
Est. expiryMar 25, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Mats Ekelund
A61K 45/06A61K 33/44A61K 9/5026A61K 9/0031A61P 1/00A61K 9/5073A61K 9/5042A61K 9/2081A61K 9/4816A61K 9/0095A61K 2300/00A61K 9/5047A61K 9/0053A61K 9/2886A61K 33/00C01B 32/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis.

Claims

exact text as granted — not AI-modified
1 - 27 . (canceled) 
     
     
         28 . A method for treating a condition selected from the group consisting of proctitis, radiation proctitis, and pouchitis in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising activated carbon, wherein the method comprises rectally administering an effective amount of a dry dose of a composition comprising particles of ground activated carbon. 
     
     
         29 . A method according to  claim 28 , wherein the activated carbon has a particle size of from 0.001 to 1 mm. 
     
     
         30 . A method according to  claim 28 , wherein the activated carbon has a particle size of from 0.02 to 1 mm. 
     
     
         31 . A method according to  claim 28 , wherein the activated carbon has a particle size of from 0.05 mm to 1 mm. (New) A method according to  claim 28 , wherein the activated carbon has a particle size of from 0.02 to 5.0 mm. 
     
     
         33 . A method according to  claim 28 , wherein the activated carbon has a particle size of from 0.6 to 1.2 mm. 
     
     
         34 . A method according to  claim 28 , wherein the activated carbon has an average particle size of from 0.2 mm to 0.3 mm. 
     
     
         35 . A The method according to  claim 28 , wherein the activated carbon has an average particle size of from 0.15 mm to 1 mm. 
     
     
         36 . A method according to  claim 28 , wherein the activated carbon has an average particle size of from 0.15 mm to 0.3 mm. 
     
     
         37 . A method according to  claim 28 , wherein the composition comprises from 450 μg to 10 g activated carbon. 
     
     
         38 . A method according to  claim 28 , wherein the activated carbon is the sole active pharmaceutical ingredient in said composition.

Join the waitlist — get patent alerts

Track US2017319617A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.